NEW YORK (GenomeWeb News) – Translational life science tools and molecular diagnostics company NanoString Technologies today filed for an initial public offering.

In its Form S-1 filed with the US Securities and Exchange Commission, the Seattle-based company said it anticipates a proposed maximum aggregate offering price of about $86.3 million, but did not provide a price range for its shares or the amount of shares to be sold.

JP Morgan and Morgan Stanley will be joint book-running managers for the offering, and Leerink Swann and R.W. Baird will act as co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.